CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 114 enrolled
Drug / intervention
Pioglitazonedrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01135394
NCT01135394N/ACompleted
CompareCT.gov

Pharmacogenomics of Thiazolidinediones

University of Maryland, Baltimore·interventional·Posted Jun 2, 2010·Updated Mar 15, 2024

In Brief

A clinical study evaluating Pioglitazone for Type 2 Diabetes. Completed, enrolled 114 participants across 1 site.

Detailed Summary

The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of medication. There is presently no way to identify this group of patients leading to unnecessary drug exposure and medication costs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2, 2010
Enrollment StartMar 1, 2009
Primary CompletionMay 31, 2018
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 16.1 years ago

Interventions

Pioglitazonedrug

30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.